



Evidence Based Guideline

Human Antihemophilic Factor (Factor VIII Human AHF)

File Name: human_antihemophilic_factor_(factor_VIII_human_ahf)
Guideline Number: EBG.MED1200
Origination: 2/1996
Last Review: 6/2002

Active guideline, no longer scheduled for routine literature review.

Description of Procedure or Service

Human antihemophilic factor (AHF, Factor VIII) maintenance therapy is used as an alternative to on-demand therapy. Its goal is to reduce the incidence of bleeding episodes and joint damage in patients with severe hemophilia A (AHF activity less than 1% of normal). In on-demand therapy, human AHF concentrate is infused when trauma or joint pain occurs from internal bleeding.

During maintenance therapy, also known as prophylactic therapy, human AHF concentrate is infused on a weekly schedule with the goal of maintaining AHF activity at a level sufficient to prevent bleeding (generally AHF activity greater than 1%).

Evidence Based Guideline for Human Antihemophilic Factor (Factor VIII Human AHF)

Human antihemophilic factor (Factor VII human AHF) may be appropriate for the treatment of severe hemophilia A (AHF activity less than 1% of normal):

- 1) To maintain the trough AHF activity at greater than 1%.
- 2) For the treatment of acute and significant bleeding.

Medical Evidence regarding Human Antihemophilic Factor (Factor VIII Human AHF) indicates it is not recommended in the following situations:

For indications or medical criteria other than stated above.

Benefits Application

Please refer to certificate for availability of benefit. This guideline relates only to the services or supplies described herein. Benefits may vary according to benefit design; therefore certificate language should be reviewed before applying the terms of the policy.

Policy: Human Antihemophilic Factor (Factor VIII Human AHF)

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable codes: J7185, J7190, J7191, J7192

Medical Term Definitions

Not applicable

Scientific Background and Reference Sources

- BCBSA Medical Policy Reference Manual
- TEC Assessment - 6/95
- Medical Policy Advisory Committee Review - 3/99
- Specialty Matched Consultant Advisory Panel - 10/2000
- Medical Policy Advisory Group - 10/2000
- Specialty Matched Consultant Advisory Panel - 6/2002

Policy Implementation/Update Information

- 2/96 Original policy issued
- 2/97 Reaffirmed
- 3/99 Reaffirmed. Medical Policy Advisory Group.
- 8/99 Reformatted, Medical Term Definitions added.
- 10/00 Specialty Matched Consultant Advisory Panel review. No change in criteria. System coding changes. Medical Policy Advisory Group review. No change in criteria. Approve.
- 6/02 Specialty Matched Consultant Advisory Panel. No changes. Approve.
- 6/03 Policy status changed to: "Active policy, no longer scheduled for routine literature review".
- 4/04 Benefits Application and Billing/Coding sections updated for consistency.
- 9/18/06 Medical Policy changed to Evidence Based Guideline.
- 8/3/09 Added new HCPCS code, Q2023, to "Billing/Coding" section. (btw)
- 1/5/10 Added new HCPCS code, J7185, to "Billing/Coding" section. Deleted Q2023. (btw)

Policy: Human Antihemophilic Factor (Factor VIII Human AHF)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.